Jean Jacques Bienaime is the chairman and CEO at BioMarin, a world leader in developing and commercializing first- or best-in-class therapies for rare genetic diseases.
Bienaimé joined BioMarin in 2005 as CEO and a member of the board of directors, bringing more than 25 years of biotechnology and pharmaceutical experience. He is credited with the company’s significant growth in revenue, employees, and stature. Under his direction, BioMarin’s market capitalization went from approximately $450 million to around $14 billion.
Prior to BioMarin, Bienaimé was the chairman, CEO, and president of Genencor, a leading biotechnology company and a pioneer in enzyme innovation.
During his tenure, the company’s revenues experienced a significant increase to more than $400 million, and in 2005, it was sold to Danisco at an enterprise value of more than $1.2 billion.
Before Genencor, Bienaimé was the chairman, CEO, and president of Sangstat Medical Corporation, where he managed revenue growth, bringing it to profitability before it was acquired by Genzyme Corporation.
Previously, he held senior management roles at Rhone-Poulenc Rorer Pharmaceuticals (now SanofiAventis), including senior vice president of worldwide marketing and business development. In this role, he was responsible for the U.S. launch of Lovenox® and the global launch of Taxotere®. He also worked for Genentech, Inc. where he was involved with the launch of tissue plasminogen activator (t-PA).
Bienaimé currently sits on the board of Incyte Corporation, as well as those of industry trade organizations, PhRMA and Biotechnology Innovation Organization (BIO). He has previously served on the boards of Portola Pharmaceuticals, Inc., InterMune, Inc., and Vital Therapies, Inc., among others.
In 2020, he was recognized as one of The Healthcare Technology Report’s “Top 50 Healthcare Technology CEOs.”
Bienaimé earned a degree in economics at the École Supérieure de Commerce de Paris and an M.B.A. from the Wharton School at the University of Pennsylvania
What is Jean Jacques Bienaime's net worth?
The estimated net worth of Jean Jacques Bienaime is at least $26.38 million as of May 10th, 2021. Mr. Bienaime owns 312,352 shares of BioMarin Pharmaceutical stock worth more than $26,378,126 as of January 20th. This net worth evaluation does not reflect any other investments that Mr. Bienaime may own. Learn More.
How do I contact Jean Jacques Bienaime?
The corporate mailing address for Mr. Bienaime and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]
Has Jean Jacques Bienaime been buying or selling shares of BioMarin Pharmaceutical?
In the last ninety days, Jean Jacques Bienaime has sold $439,300.00 in shares of BioMarin Pharmaceutical stock. Most recently, Jean Jacques Bienaime sold 5,000 shares of the business's stock in a transaction on Thursday, January 13th. The shares were sold at an average price of $87.86, for a transaction totalling $439,300.00.
Who are BioMarin Pharmaceutical's active insiders?
Are insiders buying or selling shares of BioMarin Pharmaceutical?
In the last twelve months, insiders at the biotechnology company sold shares 22 times. They sold a total of 135,546 shares worth more than $10,892,217.87. The most recent insider tranaction occured on January, 14th when Director V Bryan Lawlis sold 4,250 shares worth more than $372,342.50. Insiders at BioMarin Pharmaceutical own 1.7 % of the company.
Information on this page was last updated on 1/14/2022.